Dermata Therapeutics, Inc. (DRMA): auditor change — Dermata Therapeutics appoints Moss Adams as auditor, reports $6.6M cash, advances DMT310 to Phase 3

Dermata Therapeutics, Inc.

Appointed Moss Adams LLP as new auditor for FY2023, effective Nov 9, 2023, replacing MHM.
Cash and cash equivalents $6.6M as of Sep 30, 2023; expects to fund operations into Q2 2024.
Received positive FDA feedback on End of Phase 2 meeting for DMT310; agreed Phase 3 program acceptable for NDA filing.
Completed start-up activities for DMT310 Phase 3 STAR-1 trial; plans to initiate before end of 2023 after FDA protocol approval.
Q3 2023 R&D expenses $0.9M (down from $1.6M YoY); G&A expenses flat at $0.9M.

item 2.02 item 4.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.95

Dermata Therapeutics, Inc. engaged Moss Adams LLP as its auditor.

Action: engagement
Auditor: Moss Adams LLP

Exact text from the filing

On November 9, 2023, the Audit Committee appointed Moss Adams LLP (“ Moss Adams ”) as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dermata Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

View on SEC.gov

Browse all auditor changes →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-014015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.